1-3 of 3
Sandra J. Strauss, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Sandra J. Strauss, MD, Franck Morschhauser, MD, Martin Gramatzki, MD, Philippe Solal-Celigny, MD, PhD, Pier L. Zinzani, MD, Andreas Engert, MD, Bertrand Coiffier, MD, Dieter Hoelzer, MD, PhD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Ivan D. Horak, MD, Thomas A. Lister, MD
Journal: Blood
Blood (2005) 106 (11): 4796.
https://doi.org/10.1182/blood.V106.11.4796.4796
Published: 2005
Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD
Journal: Blood
Blood (2004) 104 (11): 1386.
https://doi.org/10.1182/blood.V104.11.1386.1386
Published: 2004
Journal Articles

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Lenushka Maharaj, MSc, Sandra J. Strauss, MD, Jim Stec, Thomas A. Lister, Simon P. Joel, PhD
Journal: Blood
Blood (2004) 104 (11): 3294.
https://doi.org/10.1182/blood.V104.11.3294.3294
Published: 2004